Josef H. von Rickenbach
Chairman of the Board and Chief Executive Officer
As Chairman and CEO of PAREXEL, Mr. von Rickenbach has taken PAREXEL from its pioneering beginnings as one of the first clinical research organizations (CROs) in the early 1980s to its place as one of the top three public biopharmaceutical services providers. He has led PAREXEL through its IPO, multiple public offerings, and over 35 mergers and acquisitions during the Company’s more than 30-year history, expanding its portfolio to meet changing client needs and market demand. Under his leadership, PAREXEL has evolved to provide a broad range of services, including globally integrated clinical development, regulatory affairs consulting, commercialization services and technologies that expedite time-to-market.
Foreseeing the globalization of clinical research, Mr. von Rickenbach worked to expand PAREXEL’s global footprint to 80 locations in 51 countries. This extensive geographical presence and the Company’s 15,560 employees allow PAREXEL to conduct clinical trials across every continent in more than 100 countries.
Through PAREXEL, Mr. von Rickenbach has made several innovative contributions to the advancement of the biopharmaceutical services industry, including conceiving of a streamlined, multi-disciplinary, systems-oriented approach to outsourced clinical development, bringing efficiencies, speed, scalability and standardization to the process. As part of the S-1 filing to the SEC, he was among the first to define the industry in formal terms. As the biopharmaceutical industry adopted information technology, Mr. von Rickenbach instituted a leading advanced technology offering, and today PAREXEL Informatics is a frontrunner in providing eClinical solutions.
Mr. von Rickenbach was twice Chairman of the Association of Clinical Research Organizations (ACRO) and was a founding member of the ACRO Board of Directors.
He was named Executive of the Year in North America in the 2010 International Business Awards, which celebrate managerial excellence worldwide. Mr. von Rickenbach also won the Ernst & Young New England Entrepreneur of the Year Award, and has also served as a judge of the program. In 2013, Mr. von Rickenbach was honored by the Massachusetts Biotechnology Council (MassBio), with their Henri Termeer Innovative Leadership Award. In 2014, he was named Immigrant Entrepreneur of the Year in Life Sciences by the Immigrant Learning Center of Malden, Mass.
Mr. von Rickenbach is a noted contributor to the New England business community, where PAREXEL’s global headquarters is based near Boston. He serves on the Board of Directors of NEHI (Network for Excellence in Health Innovation) and on the Health Policy and Management Executive Council of the Harvard School of Public Health. Additionally, he is a Vice Chair of CEOs Against Cancer, sponsored by the American Cancer Society New England Chapter, and holds Board positions on other nonprofit organizations, including San Francisco-based Life Sciences Foundation, dedicated to biotech history.
Mr. von Rickenbach’s extensive experience in the biopharmaceutical services industry puts him at the forefront of drug development and management. After beginning his career with Schering-Plough, he held positions with ENSECO (formerly ERCO). Mr. von Rickenbach holds a B.A. in Business Economics from the School of Business at the Lucerne University of Applied Sciences in Switzerland, and a Master of Business Administration from Harvard Business School.